{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T18:26:20Z","timestamp":1781029580890,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100030970","name":"Janssen-Cilag Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030970","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40744-024-00713-x","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T21:23:08Z","timestamp":1727299388000},"page":"1551-1567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Guselkumab in Biologic-Na\u00efve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip","family":"Mease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0579-1131","authenticated-orcid":false,"given":"Tatiana","family":"Korotaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8652-1410","authenticated-orcid":false,"given":"Pavel","family":"Shesternya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6353-6644","authenticated-orcid":false,"given":"Muza","family":"Kokhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7598-5586","authenticated-orcid":false,"given":"Anton","family":"Rukavitsyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2809-3929","authenticated-orcid":false,"given":"Dmitry","family":"Vasilchenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9847-2996","authenticated-orcid":false,"given":"Mohamed","family":"Sharaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5213-257X","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-1246","authenticated-orcid":false,"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,25]]},"reference":[{"issue":"21","key":"713_CR1","first-page":"2095","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(21):2095\u20136.","journal-title":"N Engl J Med"},{"issue":"3","key":"713_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105534","volume":"90","author":"JA Walsh","year":"2023","unstructured":"Walsh JA, Ogdie A, Michaud K, et al. Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: findings from a real-world study in the United States and Europe. Joint Bone Spine. 2023;90(3):105534.","journal-title":"Joint Bone Spine"},{"issue":"4\u20135","key":"713_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","volume":"13","author":"E Suzuki","year":"2014","unstructured":"Suzuki E, Mellins ED, Gershwin ME, Nestle FO, Adamopoulos IE. The IL-23\/IL-17 axis in psoriatic arthritis. Autoimmun Rev. 2014;13(4\u20135):496\u2013502.","journal-title":"Autoimmun Rev"},{"key":"713_CR4","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212594","volume":"8","author":"M Nogueira","year":"2019","unstructured":"Nogueira M, Torres T. Guselkumab for the treatment of psoriasis - evidence to date. Drugs Context. 2019;8:212594.","journal-title":"Drugs Context"},{"issue":"3","key":"713_CR5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase\u00a0III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418\u201331.","journal-title":"J Am Acad Dermatol"},{"issue":"10230","key":"713_CR6","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase\u00a03 trial. Lancet. 2020;395(10230):1126\u201336.","journal-title":"Lancet"},{"issue":"10230","key":"713_CR7","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase\u00a03 trial. Lancet. 2020;395(10230):1115\u201325.","journal-title":"Lancet"},{"issue":"3","key":"713_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","volume":"81","author":"LC Coates","year":"2022","unstructured":"Coates LC, Gossec L, Theander E, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase\u00a0IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2022;81(3):359\u201369.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"713_CR9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Rahman P, Gottlieb AB, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase\u00a0III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74(3):475\u201385.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"713_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/acr2.11523","volume":"5","author":"CT Ritchlin","year":"2023","unstructured":"Ritchlin CT, Deodhar A, Boehncke WH, et al. Multidomain efficacy and safety of guselkumab through 1\u00a0year in patients with active psoriatic arthritis with and without prior tumor necrosis factor inhibitor experience: analysis of the phase\u00a03, randomized, placebo-controlled DISCOVER-1 study. ACR Open Rheumatol. 2023;5(3):149\u201364.","journal-title":"ACR Open Rheumatol"},{"issue":"1","key":"713_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002195","volume":"8","author":"CT Ritchlin","year":"2022","unstructured":"Ritchlin CT, Mease PJ, Boehncke WH, et al. Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week\u00a052 of two phase\u00a0III, randomised, placebo-controlled studies. RMD Open. 2022;8(1):e002195.","journal-title":"RMD Open"},{"issue":"3","key":"713_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.14412\/1995-4484-2015-251-257","volume":"53","author":"OS Mishina","year":"2015","unstructured":"Mishina OS, Korotaeva TV, Starodubov VI, Nasonov EL. Incidence of psoriatic arthritis in Russia: trends at the present stage and prospects. Rheumatol Sci Pract. 2015;53(3):251\u20137.","journal-title":"Rheumatol Sci Pract"},{"issue":"1","key":"713_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","volume":"48","author":"L Scotti","year":"2018","unstructured":"Scotti L, Franchi M, Marchesoni A, Corrao G. Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2018;48(1):28\u201334.","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"713_CR14","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286\u201391.","journal-title":"J Rheumatol"},{"issue":"1","key":"713_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","volume":"70","author":"P Machado","year":"2011","unstructured":"Machado P, Landewe R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70(1):47\u201353.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"713_CR16","doi-asserted-by":"publisher","first-page":"E715","DOI":"10.1016\/S2665-9913(21)00105-3","volume":"3","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Helliwell PS, Gladman DD, et al. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase\u00a03 DISCOVER-1 and DISCOVER-2 studies. Lancet Rheumatol. 2021;3(10):E715\u201323.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"713_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40264-023-01361-w","volume":"47","author":"B Strober","year":"2024","unstructured":"Strober B, Coates LC, Lebwohl MG, et al. Long-term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase\u00a0II\/III clinical studies in psoriasis and psoriatic arthritis. Drug Saf. 2024;47(1):39\u201357.","journal-title":"Drug Saf"},{"issue":"6","key":"713_CR18","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3899\/jrheum.220928","volume":"50","author":"P Rahman","year":"2023","unstructured":"Rahman P, Boehncke WH, Mease PJ, et al. Safety of guselkumab with and without prior tumor necrosis factor inhibitor treatment: pooled results across 4 studies in patients with psoriatic arthritis. J Rheumatol. 2023;50(6):769\u201380.","journal-title":"J Rheumatol"},{"issue":"4","key":"713_CR19","first-page":"681","volume":"35","author":"E Druyts","year":"2017","unstructured":"Druyts E, Palmer JB, Balijepalli C, et al. Treatment modifying factors of biologics for psoriatic arthritis: a systematic review and Bayesian meta-regression. Clin Exp Rheumatol. 2017;35(4):681\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"713_CR20","doi-asserted-by":"crossref","unstructured":"Magee C, Jethwa H, FitzGerald OM, Jadon DR. Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review. Ther Adv Musculoskelet Dis. 2021;13:1759720X211014010.","DOI":"10.1177\/1759720X211014010"},{"key":"713_CR21","unstructured":"World Health Organization. WHO Global Tuberculosis Report 2022. https:\/\/iris.who.int\/bitstream\/handle\/10665\/363752\/9789240061729-eng.pdf?sequence=1. Accessed Aug 2024."},{"key":"713_CR22","unstructured":"World Health Organization Regional Office for Europe and the European Centre for Disease Prevention and Control. Tuberculosis surveillance and monitoring in Europe 2021. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/tuberculosis-surveillance-monitoring-Europe-2021.pdf. Accessed Aug 2024."},{"issue":"5","key":"713_CR23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.47360\/1995-4484-2020-495-502","volume":"58","author":"LS Kruglova","year":"2020","unstructured":"Kruglova LS, Korotaeva TV. Medical and social care program for patients with psoriasis and\/or psoriatic arthritis who have indications for therapy with genetically engineered biological drugs in real-world clinical practice. Rheumatol Sci Pract. 2020;58(5):495\u2013502.","journal-title":"Rheumatol Sci Pract"},{"issue":"5","key":"713_CR24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.47360\/1995-4484-2021-563-570","volume":"59","author":"E Gubar","year":"2021","unstructured":"Gubar E, Korsakova YL, Loginova EY, Korotaeva TV. Nail disease in psoriatic arthritis. Data from the Russian psoriatic arthritis registry. Rheumatol Sci Pract. 2021;59(5):563\u201370.","journal-title":"Rheumatol Sci Pract"},{"issue":"3","key":"713_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.14412\/1996-7012-2020-3-19-26","volume":"14","author":"EY Loginova","year":"2020","unstructured":"Loginova EY, Korotaeva TV, Korsakova YL, et al. The clinical status and working capacity in patients included in the All-Russian Psoriatic Arthritis Registry. Modern Rheumatol J. 2020;14(3):19\u201326.","journal-title":"Modern Rheumatol J"},{"issue":"5","key":"713_CR26","doi-asserted-by":"publisher","first-page":"622","DOI":"10.26442\/00403660.2022.05.201506","volume":"95","author":"YL Korsakova","year":"2022","unstructured":"Korsakova YL, Loginova EY, Korotaeva TV, et al. The burden of progression of psoriatic arthritis. All-Russian register data. Therap Arch. 2022;95(5):622\u20137.","journal-title":"Therap Arch"},{"issue":"2","key":"713_CR27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.14412\/1995-4484-2017-151-158","volume":"55","author":"TV Korotaeva","year":"2017","unstructured":"Korotaeva TV, Novoderezhkina EA, Stanislav ML, et al. Use of the interleukin-17A inhibitor seckinumab in psoriatic arthritis: sub-analysis of the Russian population of the international, randomized clinical trials FUTURE 1 and FUTURE 2. Rheumatol Sci Pract. 2017;55(2):151\u20138.","journal-title":"Rheumatol Sci Pract"},{"issue":"8","key":"713_CR28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465\u201379.","journal-title":"Nat Rev Rheumatol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00713-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-024-00713-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00713-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T15:12:54Z","timestamp":1731424374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-024-00713-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,25]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["713"],"URL":"https:\/\/doi.org\/10.1007\/s40744-024-00713-x","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,25]]},"assertion":[{"value":"5 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Philip Mease: Research grants from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, SUN, and UCB; consulting fees from AbbVie, Acelyrin, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Immagene, Janssen, Novartis, Pfizer, SUN, UCB, and Ventyx; and speaker fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Tatiana Korotaeva: Consulting fees from Biocad, Janssen, Novartis, and Swixx; research grant funding from Pfizer; and speaker fees from AbbVie, Biocad, Janssen, and Novartis. Pavel Shesternya: Consulting and speaker fees from AbbVie, Biocad, Janssen, Novartis, Pfizer, and R-Pharm. Muza Kokhan: Consulting fees from Celgene, Johnson & Johnson, and Novartis; grant\/research support from AbbVie, Celgene, Eli Lilly, Galderma, Johnson & Johnson, LEO Pharma, MSD, Novartis, Pfizer, and UCB; and speaker fees from AbbVie, Celgene, Eli Lilly, Galderma, Johnson & Johnson, Novartis, and UCB. Anton Rukavitsyn: Employee of Johnson & Johnson LLC, Russian Federation. Dmitry Vasilchenkov: Employee of Johnson & Johnson LLC, Russian Federation. Mohamed Sharaf: Employee of Johnson & Johnson EMEA, United Arab Emirates. Fr\u00e9d\u00e9ric Lavie: Employee of Pharmaceutical Companies of Johnson & Johnson, France. Atul Deodhar: Consulting fees for participation in advisory boards from AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, MoonLake, Novartis, Pfizer, and UCB; research grant funding from AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, MoonLake, Novartis, Pfizer, and UCB; and speaker fees from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"DISCOVER-1 and -2 were conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice. The study protocols were approved by ethics committees at each site. All participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}